Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study. The research will be presented at ...

A  scientific forum held in HCM City on April 27 announced a pioneering preventive method to help prevent lower respiratory ...

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

A new study to boost the number of expectant mothers having the Respiratory Syncytial Virus (RSV) immunisation and ...

Dr Reddy’s & Sanofi Healthcare expand partnership to unveil Beyfortus, a novel drug to prevent RSV in India: Our Bureau, Bengaluru Tuesday, April 29, 2025, 12:15 Hrs [IST] Dr Re ...

Toddlers with chronic conditions are hospitalized for RSV at twice the rate as healthy toddlers over their first two seasons. The risk was highest for children born very prematurely under 28 weeks ...

Young children with chronic conditions are more likely to be hospitalised for respiratory syncytial virus (RSV) than healthy children, according to a ...